Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Recruiting

Phase 2

Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Sponsor:

Bassam Abdulkarim

Code:

NCT02928575

Conditions

Glioblastoma Multiforme

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Sunitinib

Temozolomide

Radiation Therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Bassam Abdulkarim on 2016-10-10.